Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL18R1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL18R1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL18R1 Products |
| Gene Delivery | IL18R1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL18R1 Products |
| Benchmark Ab | Anti-IL18R1 Recombinant Antibody Recombinant positive control. |
View IL18R1 Products |
| Validator | IL18R1 siRNA Set For knockdown verification. |
View IL18R1 Products |
| Related Target A | IL18RAP Essential accessory protein forming the high-affinity IL-18 receptor complex. |
View IL18RAP Products |
| Related Target B | IL18 The primary pro-inflammatory cytokine ligand initiating signaling. |
View IL18 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species evaluation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| IL-1R subfamily counter screening | Homolog panel proteins (IL-1R1 to IL-1R9) strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IL18R1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL18R1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific constructs and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise blockade of the ternary complex (IL-18/IL-18R1/IL-18RAP) to address refractory autoimmune disorders and tumor microenvironment modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | GlaxoSmithKline, Sanofi | Asthma, COPD, Atopic Dermatitis | Ligand-blocking assays (Requires high-purity ECD-Fc) |
| Bispecific / Multi-specific | Biotech Innovators | Autoimmune Diseases, Oncology | Heterodimer validation (Requires cross-reactive antibodies & target panels) |
| Small Molecule / Inhibitors | Academic Institutes | Inflammatory Syndrome | Selectivity assays (Requires mutant vs WT recombinant proteins) |